A Multinational, Randomized, Phase II Study of the Combination of Nab-Paclitaxel and Gemcitabine With or Without Tocilizumab, an IL-6R Inhibitor, as First-line Treatment in Patients With Locally Advanced or Metastatic Pancreatic Cancer.
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 147
- 试验地点
- 2
- 主要终点
- Overall survival at 6 months
研究概览
简要总结
This is a multicenter center, 2-arms prospective randomized phase II trial which evaluates whether tocilizumab with gemcitabine/nab-paclitaxel is more effective than gemcitabine/nab-paclitaxel.
详细描述
The development of new effective treatment strategies remains a major challenge in patients with PC. High levels of IL-6 and presence of a systemic inflammatory response in PC patients have been reported to correlate with worse survival. Preclinical PC models have clearly shown that anti-IL-6-receptor antibody tocilizumab in combination with chemotherapy reduced tumor growth, number of distant metastases and the local recurrence rate. Thus, blockade of IL-6-regulated signaling pathways represents a promising approach in combination with chemotherapy. Elevated C-reactive protein (CRP) alone or in combination with hypoalbuminaemia (Modified Glasgow Prognostic Score - mGPS) are induced by IL-6 and could feasibly represent surrogate markers for IL-6 bioactivity to stratify patients likely to gain benefit through targeting IL-6.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Signed informed consent
- •Histological or cytological pancreatic adenocarcinoma. Malignant unspecified tumor cells in cytological specimen are allowed after investigator assessment, mixed histology including adenosquamous carcinoma is allowed
- •Male or non-pregnant, non-lactating females who are ≥18 years of age at the time of signing the informed consent form (ICF)
- •Non-curable unresectable locally advanced or metastatic pancreatic carcinoma.
- •A modified Glasgow Prognostic Score (mGPS) criteria of 1 or 2 assessed within 14 days of randomization as defined below:
- •mGPS of 1: CRP > 10 mg/L and albumin ≥ 35 g/L
- •mGPS of 2: CRP > 10 mg/L and albumin < 35 g/L
- •No prior antineoplastic chemotherapy or anti-cancer drugs. Patients who have received neoadjuvant or adjuvant chemotherapy and who are diagnosed with loco regional recurrent or metastatic disease are not eligible
- •ECOG/WHO Performance Status (PS) 0-1
- •≥ 4 weeks since prior major surgery, ≥ 2 weeks since prior minor surgery and ≥ 1 week since prior radiation therapy
- •Measurable disease using the RECIST1.1 criteria, defined as lesions that can be measured in at least one dimension and which have not been previously irradiated. Longest diameter ≥ 20 mm with conventional techniques or ≥ 10 mm with spiral CT scan or MRI
- •Fertile men and women of childbearing potential (defined as a sexually mature woman who (1) has not undergone hysterectomy [the surgical removal of the uterus] or bilateral oophorectomy [the surgical removal of both ovaries] or (2) has not been naturally postmenopausal for at least 24 consecutive months [ie, has had menses at any time during the preceding 24 consecutive months]) must use secure contraception methods as follows: intrauterine device, double-barrier contraception, as a condom and occlusive cap (diaphragm or cervical/vault caps) with a vaginal spermicidal agent (foam/gel/cream/suppository), vasectomized partner who is sterile prior to the female subject's entry and is the sole sexual partner for that female, or complete abstinence from sexual intercourse from before 2 months entering the study until 6 months after end of chemotherapy
- •Acceptable hematology parameters defined as:
- •Absolute neutrophil count (ANC) ≥ 1.5 x 10⁹/L
- •Platelet count ≥ 100 x 10⁹/L
- •Haemoglobin ≥ 5.6 mmol/L
- •Acceptable liver function defined as:
- •Serum bilirubin < 1.5 x upper limit of normal (ULN)
- •ASAT/ALAT < 2.5 x ULN ( < 5 x ULN with known liver metastasis)
- •Acceptable renal function with a creatinine clearance ≥ 50 mL/min/ (eg, using the Cockroft-Gault formula)
- •Subjects must have signed and dated a BIOPAC IRB/IEC approved written informed consent form in accordance with regulatory and institutional guidelines. This must be obtained before the performance of any protocol related procedures that are not part of normal subject care
排除标准
- •Electrocardiogram (ECG) with significant modifications suggesting a high risk of occurrence of angina pectoris or high risk of arrhythmia.
- •Other malignancies, except adequately treated basal carcinoma or squamous cell carcinoma of the skin or in-situ cervix carcinoma or incidental prostate cancer (T1a, Gleason score ≤ 6, PSA < 0.5 ng/ml), or any other tumor with a disease free survival of ≥ 5 years.
- •History of serious or concurrent illness or uncontrolled medical disorder; any medical condition that might be aggravated by chemotherapy treatment or which could not be controlled; including, but not restricted to:
- •Active infection requiring antibiotics within 2 weeks before the study inclusion
- •Concurrent congestive heart failure NYHA ( class III - IV )
- •Unstable angina pectoris, or myocardial infarction within 6 months and/or prior poorly controlled hypertension
- •Inflammatory bowel disease (colitis, Crohns) or other serious gastrointestinal conditions associated with risk of perforation
- •Peripheral neuropathy grade ≥ 2 according to CTCAE v 4.0
- •Concomitant use of immunosuppressive or myelosuppressive medications that would in the opinion of the investigator, increase the risk of serious neutropenic complications.
- •No known or suspected allergy to the investigational agents or any agents given in association with this trial.
- •Pregnant or lactating women.
- •Any psychological, familial, sociological, or geographical condition which does not permit protocol compliance and medical follow-up.
- •Enrollment in any other clinical protocol or investigational study with an interventional agent or assessments that may interfere with study procedures.
研究组 & 干预措施
Tocilizumab & Gemcitabine and nab-Paclitaxel
Tocilizumab:
8 mg/kg given I. V. on day 1 over 60 minutes every 28 day cycle.
Gemcitabine:
1000 mg/m² I. V. on day 1, day 8 and day 15 of every 28 day cycle.
Nab-Paclitaxel:
125 mg/m² I. V. on day 1, day 8 and day 15 of every 28 day cycle.
干预措施: Tocilizumab (Drug)
Tocilizumab & Gemcitabine and nab-Paclitaxel
Tocilizumab:
8 mg/kg given I. V. on day 1 over 60 minutes every 28 day cycle.
Gemcitabine:
1000 mg/m² I. V. on day 1, day 8 and day 15 of every 28 day cycle.
Nab-Paclitaxel:
125 mg/m² I. V. on day 1, day 8 and day 15 of every 28 day cycle.
干预措施: Gemcitabine (Drug)
Tocilizumab & Gemcitabine and nab-Paclitaxel
Tocilizumab:
8 mg/kg given I. V. on day 1 over 60 minutes every 28 day cycle.
Gemcitabine:
1000 mg/m² I. V. on day 1, day 8 and day 15 of every 28 day cycle.
Nab-Paclitaxel:
125 mg/m² I. V. on day 1, day 8 and day 15 of every 28 day cycle.
干预措施: nab-Paclitaxel (Drug)
Gemcitabine and nab-Paclitaxel
Gemcitabine:
1000 mg/m² I. V. on day 1, day 8 and day 15 of every 28 day cycle.
Nab-Paclitaxel:
125 mg/m² I. V. on day 1, day 8 and day 15 of every 28 day cycle.
干预措施: Gemcitabine (Drug)
Gemcitabine and nab-Paclitaxel
Gemcitabine:
1000 mg/m² I. V. on day 1, day 8 and day 15 of every 28 day cycle.
Nab-Paclitaxel:
125 mg/m² I. V. on day 1, day 8 and day 15 of every 28 day cycle.
干预措施: nab-Paclitaxel (Drug)
结局指标
主要结局
Overall survival at 6 months
时间窗: Approximately up to 6 months.
次要结局
- Performance status at 3 and 6 months, assessed by patient(Approximately up to 6 months.)
- Overall response rate (ORR) (ORR = CR + PR), according to RECIST 1.1.RECIST 1.1(Approximately up to 6 months.)
- Quality of Life (Quality of Life Questionnaire C30 (QLQ-C30) Version 3.0).(Approximately up to 6 months.)
- Disease control rate (DCR), (DCR = CR + PR + SD), according to RECIST 1.1.(Approximately up to 6 months.)
- Performance status at 3 and 6 months assessed by investigator(Approximately up to 6 months.)
- Progression free survival (PFS), defined as the time from the date of randomization until the earliest date of disease progression(Randomization to disease progression, or death due to any cause if sooner. Approximately up to 6 months.)
- Overall survival (OS), defined as the time from the date of randomization until death due to any cause.(Randomization until death due to any cause. Approximately up to 12 months.)
- Safety (Data on safety parameters) Safety and tolerability of the treatment regimens assessed by a summary of adverse events and clinical laboratory assessments.(Approximately up to 6 months.)
研究者
Inna Chen, MD
Staff Specialist
Herlev Hospital